Charles River Laboratories International vs Neurocrine Biosciences
Charles River Laboratories International (CRL), health care, and Neurocrine Biosciences (NBIX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Neurocrine Biosciences is worth $16.8B on the stock market and Charles River Laboratories International $15.9B: Neurocrine Biosciences is valued at 6% more. Charles River Laboratories International trades at 361 times earnings and Neurocrine Biosciences at 24.6; operating margins in their latest fiscal years were 0.63% and 21.6%. Over the past year Charles River Laboratories International's share price has moved +106% and Neurocrine Biosciences's +19.2%.
Key facts
- Charles River Laboratories International market value
- $15.9B
- Neurocrine Biosciences market value
- $16.8B
- Charles River Laboratories International P/E
- 361
- Neurocrine Biosciences P/E
- 24.6
- Charles River Laboratories International revenue
- $4BFY to 2025-12-27
- Neurocrine Biosciences revenue
- $2.9BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Charles River Laboratories International | Neurocrine Biosciences |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-27 | 2025-12-31 |
| Size | ||
| Market cap | $15.9Blower | $16.8Bhigher |
| Revenue | $4Bhigher | $2.9Blower |
| Earnings | -$144.3Mlower | $478.6Mhigher |
| Employees | 18,300higher | 2,500lower |
| Total assets | $7.1Bhigher | $4.6Blower |
| Valuation | ||
| P/E | 361higher | 24.6lower |
| P/S | 4.0lower | 5.9higher |
| P/B | 4.9higher | 4.3lower |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 0.63%lower | 21.6%higher |
| Balance sheet | ||
| Net assets | $3.2Blower | $3.3Bhigher |
| Total liabilities | $3.9Bhigher | $1.4Blower |
| Total debt | $2.1B | — |
| Cash on hand | $213.8Mlower | $713Mhigher |
| Price change | ||
| Today | -1.00%lower | +0.37%higher |
| 1 year | +106%higher | +19.2%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Joel Greenblatt0.2% / 0.1%
Charles River Laboratories International only (6)
- John Rogers3.7%
- Anthony Bozza0.9%
- Bill Nygren0.7%
- Karthik Sarma0.5%
- Ken Griffin0.2%
- Murray Stahl<0.1%
Neurocrine Biosciences only (4)
Percentages are each holding's share of that investor's reported portfolio (under "Both": Charles River Laboratories International / Neurocrine Biosciences). Who owns CRL · Who owns NBIX
More on Charles River Laboratories International
- Charles River Laboratories International (CRL) stock page
- Charles River Laboratories International market cap
- Charles River Laboratories International revenue
- Charles River Laboratories International P/E ratio
- Charles River Laboratories International operating margin
- Charles River Laboratories International total debt
- Largest health care companies
Further comparisons
Charles River Laboratories International against its closest peers
Neurocrine Biosciences against its closest peers
Learn
Questions and answers
Which is bigger, Charles River Laboratories International or Neurocrine Biosciences?
By market value, Neurocrine Biosciences is the larger: $16.8B against $15.9B for Charles River Laboratories International. By revenue in its latest fiscal year, Charles River Laboratories International is the larger: $4B against $2.9B for Neurocrine Biosciences.
Which has the higher P/E ratio?
Charles River Laboratories International: 361, against 24.6 for Neurocrine Biosciences. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Neurocrine Biosciences: 21.6%, against 0.63% for Charles River Laboratories International. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Charles River Laboratories International and Neurocrine Biosciences?
In their latest 13F filings, Joel Greenblatt holds both.
Cite this page
Funkfolio, “Charles River Laboratories International vs Neurocrine Biosciences”, data as of 18 November 2026. https://funkfolio.com/compare/crl-vs-nbix
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.